Assessing hepatitis B virus infectivity in blood components following pathogen reduction using a human hepatocyte model
This model mimics transfusion transmission by using donor-derived HBV and mouse-passaged human hepatocytes, allowing evaluation of the efficacy of different PRTs against authentic human HBV isolates. We found S-303 to be a potent inactivator of HBV.
Authors
- Rana Eltahan
- Subramanian Yegneswaran
- Santanu Biswas (ORCID: https://orcid.org/0000-0003-4056-4305)
- David R. McGivern (ORCID: https://orcid.org/0000-0003-3497-5087)
- Nina Mufti
- Carlos H. Villa (ORCID: https://orcid.org/0000-0002-4632-4751)
- Rafaelle Fares‐Gusmao (ORCID: https://orcid.org/0000-0002-2186-4145)
- Bryan J. Visser (ORCID: https://orcid.org/0000-0002-3956-1476)
Institutions
- Center for Biologics Evaluation and Research (US)
- Cerus (United States) (US)
Publication Details
- Journal
- Transfusion
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1111/trf.18357
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Energy
- Cerus Corporation
- U.S. Food and Drug Administration
- Oak Ridge Institute for Science and Education